Compare Aurora Cannabis Inc (ACB) vs Angi Inc (ANGI) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

ANGI trades at $6.44, up 6.27% today, with a bullish technical signal from moving averages but mixed oscillators. Revenue declined to $1.03B in 2025, though net income improved to $43.83M. Valuation ratios appear low with P/E of 14.86 and P/S of 0.27. Recent news highlights an AI strategy pivot and multiple law firm fraud investigations, creating uncertainty.

The stock offers potential upside to the $9.20 consensus price target, but risks include declining revenue, negative cash flows, and legal scrutiny. Analyst sentiment is cautious with 62.97% hold ratings. Execution of the AI transition and resolution of legal issues are critical for future performance.